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Research Article

Cysteine modiﬁers suggest an allosteric inhibitory
site on the CAL PDZ domain
Yu Zhao1,* , Patrick R. Cushing1,5,* , David C. Smithson2,6 , Maria Pellegrini3 , Alexandre A. Pletnev3 ,
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Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, U.S.A.; 5 PRC, LakePharma, Worcester, MA, U.S.A.; 6 DCS, Genentech, South San Francisco, CA, U.S.A.; 7 SAA,
Navigant, New York City, NY, U.S.A.; 8 RKG, School of Pharmacy, University of Kentucky, Lexington, KY, U.S.A
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Protein–protein interactions have become attractive targets for both experimental and therapeutic interventions. The PSD-95/Dlg1/ZO-1 (PDZ) domain is found in a large family of
eukaryotic scaffold proteins that plays important roles in intracellular trafficking and localization of many target proteins. Here, we seek inhibitors of the PDZ protein that facilitates
post-endocytic degradation of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR): the CFTR-associated ligand (CAL). We develop and validate biochemical screens
and identify methyl-3,4-dephostatin (MD) and its analog ethyl-3,4-dephostatin (ED) as CAL
PDZ inhibitors. Depending on conditions, MD can bind either covalently or non-covalently.
Crystallographic and NMR data confirm that MD attacks a pocket at a site distinct from the
canonical peptide-binding groove, and suggests an allosteric connection between target
residue Cys319 and the conserved Leu291 in the GLGI motif. MD and ED thus appear to represent the first examples of small-molecule allosteric regulation of PDZ:peptide affinity. Their
mechanism of action may exploit the known conformational plasticity of the PDZ domains
and suggests that allosteric modulation may represent a strategy for targeting of this family
of protein–protein binding modules.
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Protein–protein interactions play crucial roles in many biological processes, both normal and pathological. Therefore, they are attractive targets for both experimental and therapeutic interventions. However,
such interactions can be difficult to disrupt, due to their distributed contact surfaces and shallow pockets.
In the past two decades, much effort has been devoted to understand such interactions and targeting them
therapeutically. Success has been achieved by targeting protein binding sites directly. Complex chemistries
such as linear peptides, macrocycles, or more complex secondary and tertiary structures can mediate the
relatively extensive interactions that are needed to disrupt the binding interface [1,2].
One class of interactions, mediated by the PSD-95/Dlg1/ZO-1 (PDZ) domains first observed in the proteins post-synaptic density 95 (PSD-95), discs large 1 (Dlg1), and zonula occludens 1 (ZO1) [3,4], typically
engages peptides carrying short linear motifs (SLiMs). PDZ domains have been found in more than 150
human proteins. They are involved in protein trafficking and localization, signal transduction pathways,
and intercellular communications [5-7]. The canonical fold consists of two or three α-helices and five or
six β-strands. Peptide ligands bind in an extended conformation in a shallow, exposed cleft formed by
the α2 helix, the β2 strand, and a carboxylate-binding loop [8]. Due to the relatively conserved binding
mode and their roles in mediating a wide variety of physiologically important interactions, PDZ domains
have emerged as attractive targets for inhibitor development [6]. In addition to the complex chemistries, a
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Figure 1. CAL inhibitor screen

A scatter plot shows the AS (x-axis) and FRET (y-axis) corrected responses for each compound, excluding responses > +5σ.
Plate-based metrics identified AS only (green), FRET only (blue), and AS/FRET (red) responders. HSQC spectra were determined
for all double-positive and selected single-positive compounds (solid circles), and identified four candidate inhibitors (expanded
icons).

number of small molecules have been developed to inhibit different PDZ domains, all of which target the
peptide-binding cleft either competitively or through a covalent attachment [9-13].
Canonical PDZ interactions play important roles in the intracellular trafficking of cystic fibrosis (CF) transmembrane conductance regulator (CFTR). CFTR is an epithelial ion channel that is mutated in patients with CF,
a lethal genetic disease that affects roughly 70000 patients worldwide [14]. The most common variant allele is
c.1521 1523delCTT (F508del-CFTR), encoding protein p.Phe508del (F508del) in which residue Phe508 is deleted.
This mutation impairs protein biogenesis, function, and half-life. While a number of modulator therapies are emerging [15-18], selective PDZ modulation can boost efficacy of these combinations. Specifically, we have shown that the
CFTR-associated ligand (CAL), a CFTR trafficking PDZ protein, negatively regulates the apical half-life and functional activity of CFTR at the apical membrane in CF patient-derived bronchial epithelial cells expressing either
F508del- or WT-CFTR (Supplementary Figure S1). As a result, CAL PDZ inhibitors can enhance rescue of apical
CFTR abundance [19,20].
Previous studies inhibited the PDZ–CFTR interaction using either CAL-specific siRNA or peptide inhibitors,
providing proof-of-concept of the benefits of inhibiting CAL [19,21-24]. In the present study, we described the
development and initial performance of a high-throughput screening platform that identified several candidate
small-molecule inhibitors of the CAL PDZ domain. We also reported the stereochemical validation of one inhibitor
scaffold and its interaction with CAL, which suggested a mechanism of small-molecule inhibition not previously seen
for PDZ domains.

Materials and methods
Cloning of expression constructs
Cerulean fluorescent protein (a gift from Dr Nancy Speck, University of Pennsylvania) was PCR amplified and
subcloned into a pET16b vector that expresses CAL (UniProt accession #Q9HD26-2) PDZ domain (CALP)
with an N-terminal poly-histidine tag (CALP-His10 ) [20] via NcoI and NdeI restriction enzyme sites, yielding a
Cerulean-CALP fusion (Cer-CALP).
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A plasmid for expression of the CALPC319A site-directed mutant was generated from pET16b-CALP, which expresses CALP with a cleavable poly-histidine tag [25], using the QuikChange Lightning Site-Directed Mutagenesis
Kit (Stratagene).

Protein puriﬁcation and mutagenesis
CALP and CALPC319A [25] and CALP-His10 [20] proteins were expressed and purified as previously described.
Cer-CALP vector was transformed into BL21(DE3) RIL cells and protein was expressed essentially as described for
Na+ /H+ Exchanger Regulatory Factor (NHERF)1 PDZ1 [21]. Briefly, cells were induced for ∼16 h at 20◦ C and harvested by centrifugation. Following lysis by French press, the lysate was clarified by ultracentrifugation and purified using a HisTrap nickel column (GE Healthcare), and then further purified using size-exclusion chromatography (SEC) with a Superdex S75 column (GE Healthcare) equilibrated in 25 mM Tris (pH 8.5), 150 mM NaCl, 0.1
mM tris(2-carboxyethyl)phosphine (TCEP), 0.1 mM ATP, 0.02% (w/v) NaN3 . The protein was dialyzed into 25 mM
sodium phosphate (pH 7.4), 150 mM NaCl, 0.1 mM TCEP, and 5% (v/v) glycerol for cryostorage.

Peptide synthesis
All peptides were synthesized by Tufts, Keck, or St. Jude peptide-synthesis core facilities. F*-, TMR*-, and BT- prefixes
indicate peptides with N-terminal fluorescein or 5(6)-carboxytetramethylrhodamine coupled via an amino-hexanoic
acid linker or biotin (BT) coupled directly to the N-terminus, respectively. Lowercase letters in reference to peptide
sequences represent d-amino acids.

High-throughput assay automation
All screening data were generated on a High Resolution Engineering integrated screening system using Liconic plate
incubators and a Stabuli T60 robotic arm. Assay solutions were dispensed using Matrix Wellmates. Plates were centrifuged after protein/reporter solution additions using a V spin plate centrifuge. Compound transfers were performed
using a 384-well pin tool equipped with 10 nl slotted hydrophobic surface-coated pins. For all assays, the positive control was the CALP peptide inhibitor iCAL23 (WrFKKANSRWPTSII), and the negative control was an equal volume
of DMSO. Screening hits were identified on a plate-by-plate basis by calculating inhibitor cutoffs equal to the first
quartile minus 1.5 times the interquartile range.

Cer-CALP:TMR*-iCAL36 FRET screen
Cer-CALP and TMR*-iCAL36 (ANSRWPTSII) were incubated at equimolar concentrations of 2.15 μM in HTS buffer
(25 mM sodium phosphate (pH 7.4), 150 mM NaCl, 0.1 mM TCEP, 0.5 mM Thesit, 0.1 mg/ml bovine IgG) for at least
30 min, and then 25-μl aliquots were transferred to microplates. Compounds and controls were added, microplates
were centrifuged, and the solutions were allowed to equilibrate at room temperature for 1 h. The FRET ratio was
determined by measuring the ratio of TMR* to Cerulean fluorescence emission at 575 nm and 475 nm, respectively,
following excitation of Cerulean at 425 nm.

Cer-CALP:BT-iCAL38 AlphaScreen
Cer-CALP (0.42 μM) and BT-iCAL38 (WrFKKfNSRWPTSII; 1.0 μM) were mixed for 30 min in AlphaScreen (AS)
buffer (HTS buffer without sodium azide). Fifteen microliters of protein and peptide solution was transferred to
microplates. Compounds and controls were subsequently transferred to the microplates and were allowed to incubate
for 30 min followed by 10 μl nickel chelate and streptavidin AS beads, yielding a final concentration of 20 μg/ml beads
with 0.25 μM Cer-CALP and 0.6 μM BT-iCAL38. Solutions were incubated for another 45 min prior to measurement
of emission from 520–620 nm upon excitation at 680 nm in an EnVision microplate reader (Perkin Elmer).

Fluorescence polarization
Fluorescence polarization (FP) experiments were performed as previously described [21]. For K D measurements,
30 nM reporter ligand (F*-iCAL36) was incubated with serial dilutions of protein for 30 min at room temperature
before measurement of fluorescence anisotropy data. Protein was diluted in FP buffer (25 mM sodium phosphate,
150 mM sodium chloride, 0.02% (w/v) sodium azide, 0.1 mM TCEP containing 0.1 mg/ml IgG and 0.5 mM Thesit).
For K I measurements, 30 nM of the same reporter ligand was incubated with protein at a concentration of 1.8*K D
for 30 min at room temperature. An aliquot of 38 μl of this protein:reporter mixture was then incubated with 2 μl of
serial dilution of the inhibitor for 30 min at room temperature before measurement. Titrations were fit as previously
described [21].
c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Apparent K D measurements for modiﬁed proteins

Aliquots of 50 μM CALP or CALPC319A were incubated separately with one of three small molecules at a concentration of 500 μM for ∼4 h at RT: methyl-3,4-dephostatin (MD), ethyl-3,4-dephostatin (ED), or N-ethyl-maleimide
(EM). Excess small-molecule label was removed through dialysis (two 2-h buffer exchanges). The dialyzed proteins were immediately used in a FP binding assay, and the K D was determined, as previously described [21]. The
buffer used for incubation, dialysis, and FP measurements contained 25 mM sodium phosphate, 150 mM sodium
chloride, and 0.02% (w/v) sodium azide (labeling buffer) at pH 6.8. The extent of small-molecule adduct formation
was quantitated by integrating the peaks observed by MALDI-TOF MS at the corresponding unlabeled and labeled
molecular weights. Covalent protein dimerization was assessed by non-reducing SDS/PAGE. A preliminary set of
labeling experiments was performed for ∼48 h at 4◦ C, using 243 μM protein and 270 μM compound, and 25 mM
Tris(hydroxymethyl)aminomethane (pH 9) instead of sodium phosphate; dialysis was performed overnight in labeling buffer at pH 7.4.

CALP isotopic labeling
CALP was isotopically labeled either with 15 N or with 15 N and 13 C as follows. BL21(DE3) RIL cells were grown
overnight at 37◦ C in 2×YT. To initiate labeling, cells were washed twice by centrifugation, decantation, and resuspension in minimal medium. Cells were then diluted 100:1 in minimal medium and grown at 37◦ C. Lysis and
purification were performed as described for unlabeled CALP [20,25]. Minimal medium contained, in addition
to 0.1 mg/l ampicillin, 0.037 mg/l chloramphenicol, 1× BME vitamins (Sigma), and 5 mg/l thiamine (in mM): 50
KH2 PO4 , 30 Na3 C6 H5 O7 *2H2 O, 0.7 CaCl2 *2H2 O, 10 MgSO4 *7H2 O, 1 FeCl3 *6H2 O, 0.09 ZnCl2 , 0.12 CoCl2 *6H2 O,
0.075 CuCl2 *2H2 O, 0.083 Na2 MoO4 *2H2 O, 0.068 CaCl2 *2H2 O, 0.0745 H3 BO3 , 0.12 HCl. Minimal medium also
contained 3 g/l 15 N-NH4 Cl and 10 g/l glucose for expression of 15 N-CALP or 3 g/l 15 N-NH4 Cl and 4 g/l 13 C-glucose
(Cambridge Isotope Laboratories) for expression of 13 C/15 N-CALP. 15 N-CALP-His10 was expressed and purified as
previously described [20,21].

NMR spectroscopy

NMR experiments were conducted at 25◦ C on a Bruker 600 MHz spectrometer, equipped with a TCI cryogenic probe.
Two CAL PDZ constructs were used for NMR: CALP-His10 [21] and tag-free CALP [25]. 15 N-CALP-His10 was used
only for the initial validation of the 12 FRET+ /AS+ candidates (Supplementary Figure S2). Backbone assignments
for tag-free CALP were achieved using 755 μM protein through 2D 1 H-15 N heteronuclear single quantum coherence (HSQC) and 3D HNCA, HN(CO)CA, HNCACB, and CBCA(CO)NH experiments following dialysis into 25
mM sodium phosphate pH 6.8, 50 mM NaCl, 0.1 mM TCEP, 0.02% NaN3 (NMR buffer). Eighty-one of eighty-two
non-proline residues were assigned. All NMR HSQC binding spectra with CALP were collected with 50 μM protein.
iCAL1155, MD, and iCAL1113 dose–response measurements were conducted with 5% (v/v) D6 -DMSO throughout.
Due to slow exchange, fractional occupancy was determined by integrating cross-peaks for a given residue at both the
first bound and unbound positions as a function of ligand concentration using Sparky, and then dividing the bound
value by the sum. Fractional occupancy values at each concentration were averaged for at least six residues, and the resulting titration data were fit by a four-parameter logistic curve √
to determine EC50 . For small-molecule footprinting,
chemical-shift perturbations () were normalized using  = ((1 H)2 + (15 N/6)2 ); cross-peaks that exhibited
perturbations 3*S.D.> () ≥2*S.D. were labeled orange, and () ≥3*S.D. were labeled red in (Figure 2B,E,H). Compound footprints were visualized using a model of the structure of the CAL PDZ domain (PDB ID 2LOB) using
PyMOL [26].

Crystallization, data collection, and processing
Crystals were obtained and diffraction data were collected and processed as previously described [25,27]. For
co-crystallization, 5 mg/ml CALP was supplemented with 1 mM peptide HPV18E6 (RLQRRRETQV) and 1 mM
MD at 2% (v/v) DMSO final concentration. For mutant co-crystallization 5 mg/ml CALPC319A was supplemented
with 1 mM peptide HPV18E6, and after crystals had formed, MD was added to the drop at ∼10 mM with 10% (v/v)
DMSO final concentration. For the CALP co-crystal, 0.3◦ oscillation images were collected over 360◦ at 100 K at
the X6A beamline of the National Synchrotron Light Source at Brookhaven National Laboratory. For the CALPC319A
co-crystal, 0.3◦ oscillation images were collected over 210◦ at 100 K at the beamline 14-1 of the Stanford Synchrotron
Radiation Lightsource (please refer to Table 1 for more information). XDS [28] was used to process the diffraction
images. The crystal structure of the CALP:iCAL36 complex (PDB ID: 4E34) was used as a molecular replacement
search model. Phenix [29,30] and Wincoot [31] were used for structure refinement and PyMOL [26] was used to
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Figure 2. NMR HSQC footprint of candidate compounds

HSQC spectra are shown for 50 μM 15 N-CALP with either 1 mM iCAL1113 (A), 1 mM iCAL1155 (D), or 125 μM MD (G) in blue
overlaid with control spectra collected in the presence of vehicle only (5% DMSO, red). Selected chemical-shift perturbations are
identified. Significant cross-peak perturbations for iCAL1113 (B), iCAL1155, (E), and MD (H) after compound addition are highlighted
by coloring the affected residues on the van der Waals surface (top (B,E,H) panels) of the CAL PDZ domain (PDB ID: 2LOB; orange:
≥2σ; red: ≥3σ). Arrows indicate the location of the β1 strand and α1 helix. All compounds bind in a pocket between β1 strand
and α1 helix, as indicated in the cartoon model ((B,E,H) bottom panels). HSQC titrations were performed with each compound and
fractional occupancy was calculated at each concentration by integrating slowly exchanging cross-peak volumes at both bound
and unbound positions. Results were averaged for six cross-peaks. Averages (+
−S.D.) are plotted as a function of compound
concentration (C,F,I). The EC50 was calculated by least-squares fitting to a logistic curve (solid line), as described in the ‘Materials
and methods’ section.
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Table 1 Data collection and reﬁnement statistics
CALP + MD + HPV18E6

CALPC319A + HPV18E6

Data collection
Wavelength (Å)

0.9795

0.9795

Space group (number)

P 21 (4)

P 21 (4)

Unit cell dimensions:
a, b, c (Å)

32.8, 48.3, 51.6

32.7, 48.3, 51.4

α, β, γ (◦ )

90.0, 101.5, 90.0

90.0, 101.8, 90.0

Resolution (Å)

19.29–1.70 (1.81–1.70)*

18.79–1.36 (1.46–1.36)*

Rsym † (%)

6.2 (68.6)*

5.3 (61.8)*

I/σI

23.78 (3.34)*

17.23 (3.09)*

Completeness (%)

99.7 (99.5)*

99.1 (99.1)*

Redundancy

7.51 (7.51)*

4.26 (4.26)*

Reﬁnement
Total reﬂections

17472

33527

Test-set reﬂections

858

1700

17.4/22.6

15.4/18.3

§

Rwork ‡ /Rfree (%)
Number of atoms:
Protein/peptide

1457

1607

Solvent

144

143

Ligand

12

0

99.46/0.54/0.00

99.50/0.50/0.00

Protein

23.68

22.04

Solvent

33.72

37.03

Ligand

69.63

0.00
0.006

Ramachandran plot (%)
Bav (Å2 )

Bond length RMSD (Å)

0.007

Bond angle RMSD (◦ )

1.059

0.879

PDB ID

5IC3

5K4F

* Values

in parentheses are for data in the highest resolution shell.
=  h  i —I(h) – Ii (h)—/ h  i Ii (h), where Ii (h) and I(h) values are the i-th and mean measurements of the intensity of reﬂection h.
‡R
work =  h —F obs (h) – F calc (h)—/ h F obs (h), h ∈ {working set}.
§R
free =  h —F obs (h) – F calc (h)—/ h F obs (h), h ∈ {test set}.
 Favored/allowed/outliers.
†R

sym

generate the images of the model. For the wild-type CALP structure, density for MD was seen after the second round
of refinement, and MD was added to the model in the third round of refinement. As expected, no additional density
was seen in the vicinity of Ala319 for the CALPC319A crystals; hence MD is not present in the final model of the mutant.

CAL knockdown and CFTR surface biotinylation
CFBE 41o- CF bronchial epithelial cells expressing WT CFTR (CFBE-WT cells) or F508del (CFBE-F cells) [32]
were a generous gift from Dr J.P. Clancy (University of Alabama, Birmingham). CFBE-WT cells were treated with
CAL-specific (siCAL, 200 nM) or control (siNEG, 200 nM) RNAi mixed with HiPerFect (Qiagen) transfection agent
and Opti-MEM (Gibco) and seeded on plastic dishes for 24 h. The next day, cells were harvested and reseeded on 4.67
cm2 surface area and 0.4 μm pore size Transwell permeable supports (Corning) coated with collagen. Apical medium
was removed 24 h post seeding, and cells were grown at air–liquid interface for 3 days prior to surface biotinylation.
Transwell plates were kept on ice throughout the surface-biotinylation procedure. Filters were washed with cold
phosphate buffer saline (Gibco), PBS ++, pH 7.4 (PBS supplemented with 1 mM MgCl2 and 0.1 mM CaCl2 ). PBS++
was added to the basolateral side of the filter while 0.5 ml NHC-LC-BT dissolved in PBS++, pH 7.4 (1 mg/ml; Thermo
Scientific) was added to the apical surface. Plates were incubated in the dark at 4◦ C for 1 h. Filters were then washed on
both sides with PBS++, pH 7.4 and incubated with 500 μl BLB/1XC (25 mM HEPES, pH 8.0, 1% (v/v) Triton X-100,
10% (v/v) glycerol, and Complete protease inhibitor (Roche) for 15 min on a shaker at 4◦ C. Cells were scraped and
lysates passed through a 27-gauge half-inch needle before spinning in a Biofuge (Heraeus) at 13000 rpm at 4◦ C for 15
min. For surface-biotinylated proteins, the lysate was incubated with washed streptavidin beads and incubated at 4◦ C
for 2 h. Samples were washed with BLB/1XC (25 mM HEPES, pH 8.0, 1% (v/v) Triton X-100, 10% (v/v) glycerol, and
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Complete protease inhibitor (Roche)) for 15 min on a shaker at 4◦ C. Bound protein was eluted with Laemmli sample
buffer at 85◦ C for 3 min. Samples were loaded on SDS/PAGE (7.5% gels) and blotted on to PVDF membranes; the
blots were probed with the CFTR-specific antibody 596 (provided through the CF Foundation).

Biocompatibility assays
CFBE-F cells were used for both biocompatibility assays. Cell proliferation was determined by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)
R
AQueous One Solution Cell Proliferation Assay [MTS], Promega). The MTS formazan product
assay (CellTiter 96
generated in each condition was quantitated after 24 h of treatment with each compound of interest. The values were
normalized to the response of a control exposed to medium only.
Cell permeability was determined by lactate dehydrogenase (LDH) assay to assess cytotoxicity (CytoTox 96TM
Non-Radioactive Cytotoxicity Assay, Promega). The LDH released in each condition was quantitated after 24 h of
treatment with each compound of interest. The values were normalized to the control response to 0.1% Triton X-100.
In both the MTS and LDH assays, MD and iCAL1155 introduced 0.2% (v/v) DMSO into the system; iCAL1113
introduced 0.5% (v/v) DMSO into the system.

Data availability
Co-ordinates and structure factors have been deposited in the Protein Data Bank with accession numbers 5IC3 (CALP
with HPV18E6 peptide and MD) and 5K4F (CALPC319A with HPV18E6 peptide). The NMR assignment for CALP
has been deposited in the Biological Magnetic Resonance Bank (BMRB) with accession number 27338.

Results and discussion
A screen for small-molecule inhibitors of CAL PDZ domain
To identify small molecules that could disrupt the interaction between PDZ-binding motifs and CAL, we designed
high-throughput compatible assays using our peptide inhibitor iCAL36 (ANSRWPTSII) as a reporter for CALP binding [19,33]. To validate our approach, we screened a library of 5600 bioactive compounds (Figure 1), representing
3161 distinct chemistries. In preliminary experiments with carboxy-X-rhodamine- or fluorescein-labeled reporter
peptides, FP competition assays exhibited relatively poor Z and Z values (≤0.53 and ≤0.39, respectively), and a relatively large number of the putative candidates showed significant fluorescence intensity shifts (data not shown). As
a result, parallel FRET and AS proximity assays were tested as alternative primary screens.
For the FRET assay, we developed overexpression and purification protocols for a Cer-CALP fusion constructed to
serve as a donor to a TMR*-labeled reporter peptide. FRET was determined by the ratio of TMR* to Cerulean fluorescence at 575 and 475 nm, respectively, following excitation of Cerulean at 425 nm. Equimolar titration of Cer-CALP
and TMR*-iCAL36 revealed an EC50 value of 4.9 μM, consistent with the expected high-affinity protein–reporter
interaction. When tested in our pilot bioactive screen in 384-well format, the Z and Z factors were 0.71 and 0.70,
respectively. We selected candidates with FRET signals that were simultaneously outliers from the negative-control
and variable-compound populations for statistical robustness [34]. The hit rate was 4.1% of wells (231/5600).
We also developed an AS assay using the Cer-CALP fusion protein and an N-terminally biotinylated reporter
peptide. Titration of BT-iCAL38 in the presence of 0.25 μM Cer-CALP confirmed a high-affinity interaction (EC50
= 0.38 μM). In high-throughput screening (HTS) format with our bioactive screen, the AS assay yielded Z and Z
factors of 0.73 and 0.75, respectively. The hit rate was 3.7% of wells (209/5600).
Both the FRET and AS assays demonstrated significantly improved Z and Z factors relative to our initial FP protocols. However, they both also showed relatively high hit rates. Of the 3161 unique compounds, the FRET assay
identified 166 distinct compounds (5.3%; red and blue circles in Figure 1), whereas 161 were identified by AS (5.1%;
red and green circles in Figure 1). Most of the hits were clustered along the respective thresholds. Nevertheless, by
examining compound redundancy, we confirmed the reproducibility of the results within each assay. For example,
there are 547 compounds presented twice in the library. Of the 547 duplicated compounds, 530 gave the same results
in FRET assay; 539 gave the same results in AS assay. Across all replicated compounds, >95% of the decisions were
‘unanimous.’

Validation and analysis
Given the differences between the two assays, we initially focussed on the relatively small number of compounds
(12 hits, 0.4%) that were identified in both (Figure 1, red symbols and Supplementary Figure S2). One compound
fell beyond the range of the positive control and was not pursued further. Amongst the remaining 11 candidates,
c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Inhibitor biocompatibility

The biocompatibility of the three candidate inhibitors iCAL1113, iCAL1155, and MD was assessed using CFBE-F cells. Compound
concentration was set at 50 μM. (A) Cell proliferation assay. The values were normalized to the response of a control exposed to
medium only. MD-treated cells proliferate as well as DMSO controls; iCAL1155- and iCAL1113-treated cells showed much less
proliferation. (B) Cytotoxicity assay. The values were normalized to the control response to 0.1% Triton X-100. The toxicity of MD is
comparable with DMSO control. iCAL1155- and iCAL1113-treated cells released significantly more LDH, indicating that iCAL1155
and iCAL1113 are more toxic at the same concentrations. In both assays, data represented mean +
− S.E.M. Significance was tested
by a two-tailed, unpaired Student’s t test compared with control, as indicated. TX100 marks the response to 0.1% Triton X-100.

HSQC footprints of the CAL PDZ domain identified seven direct interactors (58% true positives). Five of these cause
global changes consistent with destabilization of the protein fold. The remaining two compounds, iCAL1155 and
MD, caused residue-specific chemical-shift perturbations (Figure 2D,G) and were selected for further evaluation.
To assess the false-negative implications of selecting only FRET+ /AS+ hits, we also tested 119 FRET+ /AS– and 30
FRET– /AS+ hits by NMR. From this much larger pool, only five compounds were validated by NMR footprinting, and
only one compound from each set exhibited a site-specific footprint, underscoring the predictive value of combining
methodologically distinct primary assays.
We then titrated the progression of chemical-shift perturbations in HSQC spectra to estimate an EC50 value for
each of the confirmed inhibitors. The AS-positive compound iCAL1121 did not achieve saturation at 2 mM and was
dropped from further study. The FRET-positive compound iCAL1113 and the double-positive compounds iCAL1155
and MD exhibited EC50 values ranging from 48 to 154 μM (Figure 2C,F,I).
Furthermore, while iCAL1113 and iCAL1155 cause cytotoxic and cytostatic effects when applied to CFBE-F
monolayers, MD exhibits relatively good cellular biocompatibility in both assays (Figure 3). We thus performed an
Ussing-chamber assay to test whether MD could rescue functional F508del-CFTR. However, MD fails to stimulate
CFTR chloride currents when applied to CFBE-F cells (Supplementary Figure S3), which might be due to limited
potency, lack of specificity, or inability to access the endocytic pathway.
Indeed, MD contains a catechol moiety and is thus probably one of the pan–assay interference compounds (PAINS)
[35]. MD inhibits multiple targets, including several protein tyrosine phosphatases, such as CD45, PTP1B, and SHPTP1, as well as APOBEC3G, a cytosine deaminase with a role in the innate immune response. It also covalently
modifies proteins [36-40]. Therefore, from a therapeutic perspective, MD is unlikely to represent a CF drug scaffold.

Identifying the binding pocket of MD
Nevertheless, as shown in Figure 2H, the HSQC footprint of MD revealed a binding pocket on CAL PDZ domain
that is distinct from the canonical peptide-binding pocket of the protein. We therefore suspected that our screen
might have identified allosteric inhibitors and wished to visualize the effect of MD binding on CALP structure and
peptide-binding affinity. Unfortunately, crystallization trials with CALP and MD generated thin needle-shaped crystals that did not yield structural information. However, we were able to obtain crystals and high-resolution diffraction data for CALP in the presence of high concentrations of both MD and a low-affinity peptide partner HPV18E6
(RLQRRRETQV) [41]. Following structure determination and refinement (Table 1), we could clearly identify the
PDZ domain and the bound peptide. In addition, we observed a positive peak in the difference in electron density
map (Figure 4) located not in the CALP peptide-binding cleft, but rather in the vicinity of the footprint identified by
NMR, consistent with an allosteric model (Supplementary Figure S4). This electron density is located on the other
side of the carboxylate-binding loop that forms one end of the peptide-binding cleft and interacts with the main-chain

8

c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution

License 4.0 (CC BY).

Bioscience Reports (2018) 38 BSR20180231
https://doi.org/10.1042/BSR20180231

Figure 4. Covalent modiﬁcation of CALP with MD

(A) Positive F O – F C difference omit (green mesh, 2.5σ) and refined 2F O – F C electron density (gray mesh, 0.5σ) is observed adjacent
to the Cys319 side chain (cyan carbons) for covalently attached MD (green carbons). (B) Alignment of the covalent adduct (cyan
carbons) and the MD-free peptide complex (PDB ID: 4JOR; gray carbons) shows the rotation (arrow) of the Cys319 side chain
required to accommodate the attachment of MD. (C) Heterotrimer structure (PDB ID: 5IC3) of CAL PDZ with a peptide (HPV18E6)
and an inhibitor (MD) bound shows the spatial relationship between CALP (pale cyan), peptide HPV18E6 (red), cysteine side chain
(cyan) and MD (green carbons). The non-covalent binding site of MD is in the general region of the covalent attachment site.

carboxylate of the peptide. The crystallographic structure locates the MD binding site in the vicinity of Cys319 , the
only cysteine side chain in CALP. Compared with the previous MD-free structures, the cysteine side chain has rotated around its χ1 angle, reorienting the thiol toward the new density. In concert, the GLGI loop moves away from
the peptide binding cleft by 1 Å (Supplementary Figure S5A). Otherwise, the WT and modified structures are very
similar (RMSD = 0.213 Å).

Modeling the structure of the MD–CALP complex
As mentioned above, MD has previously been shown to interact covalently with sulphydryl groups [36]. Using direct
infusion ESI-Orbitrap MS, we confirmed that under crystallization conditions, a single molecule of MD covalently
modifies CALP (Supplementary Figure S6A,B). We localized this modification to Cys319 via manual annotation of
product–ion spectra.
In the MD analog ED, the –NO group of the N-methyl-N-nitroso moiety is considered a leaving group, and some
studies have used ED as a nitric oxide donor to protect neurones from apoptosis [42,43]. However, loss of the nitroso
moiety would result in a cysteine adduct of MD that fits poorly within the observed electron density. Furthermore,
MS of both intact CALP and peptide digests following covalent modification (Supplementary Figure S6A,B) indicated that MD loses only a single proton after forming an adduct with CALP. The crystallographic structure of an
APOBEC3G-MD adduct showed a covalent bond formed between the cysteine thiol and the 6 (ortho) position on
the benzene ring of MD [36], a modification consistent with our MS data for CALP-MD. In our CALP-MD:peptide
crystal structure (Figure 4), the same chemistry of attachment also yielded the best fit to the experimental electron
density. The corresponding MD moiety is thus included in the refined structure.

Covalent and non-covalent interactions with CALP
CALP–MD adduct formation is highly sensitive to pH, temperature, time, and concentration. According to
MALDI-TOF results, Cys319 was extensively modified (>85%, n=3) under crystallization conditions, but much less
strongly modified (≤13%, n=3) under NMR conditions at MD concentrations ≤125 μM or FRET screening conditions (Supplementary Figure S6C–E).
NMR titration data support the hypothesis that MD can interact with CALP both covalently and non-covalently,
acting in both cases at a site near Cys319 . The progressive disappearance of cross-peaks corresponding to the unbound
state of CAL PDZ and the appearance of new cross-peaks for a subset of residues indicates that the binding is in slow
exchange in the NMR timescale, consistent with an affinity in the low-to-mid micromolar range [44]. This effect
appears at 15 μM MD and reaches saturation at 125 μM, where the signals from the unbound state are almost absent.
Interestingly, at still higher concentrations, a new set of cross-peaks appear for some of the initially perturbed residues,
corresponding to a second bound state (Figure 5). In parallel, cross-peaks corresponding to the first bound state start
to decrease in intensity. The second bound state appears at 250 μM and saturates at 1 mM. From 250 μM on, only the
c 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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(A)

(D)

(B)

(C)

Figure 5. NMR HSQC titration of MD

HSQC spectra are shown for 50 μM 15 N-CALP with either 125 μM (blue) or 500 μM MD (green) overlaid with control spectra
collected in the presence of vehicle only (5% DMSO, red). Two-step movement was observed for several residues across the
titration from 15 to 500 μM. For example, the G321 peak (A) shifted upfield at 125 μM (B), and then downfield at 500 μM (C). The
overlaid full spectra are shown in (D), with G321(black box) and L291 (red box) highlighted.

two perturbed states are observed, with the second progressively replacing the first. Consistent with the dose–response
of this second transition, when we track the modification status of CALP under NMR conditions by MALDI-TOF, we
observe significant formation of CALP-MD adducts starting at 250 μM and increasing in a dose-dependent fashion
(Supplementary Figure S7).
It is worth noting that most of the cross-peaks involved in the first bound state subsequently transition as a group
to the second bound state, presumably reflecting binding to a similar site on CAL PDZ but via a different binding
modality. Taken together, these observations are consistent with a model in which MD initially non-covalently docks
to the CAL PDZ domain and subsequently forms a covalent bond. Interestingly, the chemical shifts associated with
Arg318 and Leu291 exhibit much larger perturbations (>2σ) in the second bound state than in the first. For Arg318 ,
this likely reflects the fact that it is adjacent to Cys319 . However, the change at Leu291 cannot be accounted for by a
local perturbation: it is located 10.5 Å away at the other side of the protein.

Role of Cys319 in CALP inhibition
To assess the relative importance of the covalent and non-covalent interactions on MD’s ability to inhibit peptide
binding, we sought to eliminate the target thiol moiety and thus prevent the covalent interaction with MD, while
preserving the non-covalent affinity. We mutated Cys319 to alanine (CALPC319A ) and performed an HSQC titration
with 15 N-CALPC319A . However, no chemical shift perturbations were detected up to an MD concentration of 500 μM
(Supplementary Figure S8). At higher concentrations, precipitation was observed. Since chemical-shift perturbations
of WT CALP were seen at concentrations as low as 15 μM MD, it is likely that both the covalent and non-covalent
interactions between MD and CAL PDZ are strongly perturbed by the C319A mutation.
We also co-crystallized CALPC319A and peptide HPV18E6, with ∼10 mM MD added to the drop after crystallization, and determined the structure of the resulting complex (Table 1; PDB ID: 5K4F). Electron density is observed
only for the PDZ domain and the peptide. We did not observe any electron density that might correspond to MD in
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Figure 6. The schematics of MD oxidation

(A) MD can be oxidized from the catechol form to the quinone form; (B) the quinone form of MD can react with cysteine thiol and
return to the more stable catechol form after the nucleophilic attack is complete.

the CALPC319A :MD:peptide structure, consistent with the loss of both non-covalent and covalent interactions seen
by NMR. The C319A mutation does not affect the overall structure of the PDZ domain (Supplementary Figure S5B,
RMSD = 0.213 Å). Curiously, the GLGI loop showed the same movement that was observed in the CALP:MD:peptide
crystal structure (Supplementary Figure S5B,C). Therefore, the physical displacement is unlikely to represent the
mechanism for allosteric cross-talk between the inhibitor and peptide-binding sites, associated with the covalent
modification of MD.

The chemistry of MD modiﬁcation
The mutagenesis strategy did not allow us to isolate the non-covalent mode of interaction of MD with the CAL PDZ
domain. As an alternative, we sought to understand and exploit the chemistry by which MD can covalently modify
cysteine thiol groups, which has not been previously described in detail. As described above, based on our MS and
crystallographic data, the –NO leaving group is not involved, so the mechanism presumably involves an attack on
the 6-carbon of the ring, which is unlikely in the catechol form. However, MD can undergo a redox reaction that
allows the moiety to shift between catechol, semiquinone radical, and ortho-benzoquinone states [45]. Since MD has
a relatively electron-rich arene, we hypothesized that MD may be oxidized to its quinone form (Figure 6A) before
undergoing a nucleophilic attack by the cysteine thiol (Figure 6B). Such redox interconversions are also hallmarks
of certain PAINS compounds [35]. We hypothesized that higher pH would promote the loss of a proton on one of
the hydroxyl groups, favoring oxidation of the catechol by molecular oxygen to yield the quinone form (Figure 6A).
In 1 H NMR spectra of MD in aqueous solution (Figure 7), we observed a primary set of resonances associated with
the catechol form and a secondary set of resonances consistent with the quinone form [46]. At pH 6.8, we observed
only 3% of MD in the quinone form, compared with 19% in the quinone form at pH 9. Based on this mechanism,
reducing agents should also be able to prevent MD from covalently modifying cysteines, by inhibiting oxidation of
the MD catechol to a quinone [47].

Inhibitory effect of covalent compared with non-covalent modiﬁcations
As a result, we can leverage the chemistry of the FP binding assay, which is compatible with 100 μM TCEP in the
buffer, to suppress the covalent modification of CALP (Supplementary Figure S6D), and thus explore the impact
of the non-covalent interaction. Under these conditions, FP displacement titrations showed no inhibitory effect of
MD (Supplementary Figure S9A). They also showed no displacement by the close chemical analog ED nor by the
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Figure 7. More MD oxidation was observed at higher pH in proton NMR spectra

The ortho and meta protons of the benzene ring of MD have different chemical shifts between the catechol (a, b, c) and the quinone
(a’, b’, c’) forms. MD (1 mM) was dissolved in buffer containing either 10 mM sodium phosphate pH 6.8 (A) or Tris pH 9 (B), 150
mM NaCl, 1% DMSO-D6 and 1% D2 O. 1D-proton spectra of MD in different buffers were collected at 298 K. At pH 9, 19% of the
total MD was observed in the oxidized quinone form according to the integrated proton peak area. However, only 3% of the total
MD was oxidized to the quinone form at pH 6.8.

common, unrelated cysteine modifier EM (Supplementary Figure S9A), included as a control for the stereochemical
specificity of the modification required at Cys319 .
As a next step, to investigate the impact of the covalent modification, we labeled CALP with either MD, ED, or
EM, and then used dialysis to remove excess compound. We then performed MALDI-TOF, to confirm the extent of
modification, and FP titrations, to determine apparent K D values. Initial experiments under stringent labeling and
dialysis conditions strongly favored adduction, but also led to the formation of reversible covalent PDZ dimers in
the presence of the dephostatin compounds, confounding analysis of the FP data. Using less aggressive conditions
and relatively rapid dialysis, we were able to obtain substantial covalent modification (>75%; Supplementary Figure S9D–F) with much lower levels of PDZ dimer formation in the presence of MD or ED (<16%). This approach
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Table 2 KD calculations for native and modiﬁed CAL PDZ
DMSO

MD

ED

EM

1.29 +
− 0.16

1.22 +
− 0.17

CALP
2.43 +
− 0.36

2.45 +
− 0.42

P-value compared with CALP (DMSO)

0.0001

0.0001

0.60

% covalent modiﬁcation

79–81%

76–81%

90–92%

1.51 +
− 0.22

1.46 +
− 0.21

1.51 +
− 0.15

0.48

0.18

0.48

0%

0%

7–9%

K D (μM)

CALPC319A
K D (μM)
P-value compared with CALPC319A (DMSO)
% covalent modiﬁcation

1.56 +
− 0.30

Chemical structures

K D values are mean +
− S.D.
Schematics show the chemical structures of MD, ED, and EM. The blue arrows indicate the sites of covalent attachments to cysteine thiols. The red
moieties corresponding to the methyl (MD) and ethyl (ED) substituents.
DMSO, MD, ED, and EM treatments and the FP measurements of CALP and CALPC319A were performed in parallel. Statistics were calculated from
three independent experiments using linear mixed effect model in R (package nlme).

yielded reproducible FP titration curves. The resulting apparent equilibrium dissociation constants reflect the impact
of covalent small-molecule modification on peptide affinity.
The MD-modified domain (CALP–MD) showed a 1.9-fold loss of apparent affinity compared with the
DMSO-treated control protein. The ED-modified domain (CALP–ED) showed a similar 1.9-fold loss of apparent
affinity. Both of these offsets were statistically significant. In comparison, EM-modified CALP (CALP–EM) showed
no significant affinity change compared with the DMSO-treated protein, confirming the importance of the dephostatin scaffold in the observed inhibition (Supplementary Figure S9B and Table 2).
To test the hypothesis that the observed loss of affinity is really due to modification at Cys319 as opposed to some
other chemical effect, we performed equivalent measurements following the treatment of the CALPC319A mutant. Using the same labeling conditions, we observed neither modification (Supplementary Figure S9G–I) nor inhibition of
the mutant protein (Supplementary Figure S9C and Table 2). Taken together, our data are consistent with a model in
which covalent modification of Cys319 is primarily responsible for CALP inhibition mediated by dephostatin compounds.

Concluding remarks
Although of limited utility as therapeutic scaffolds, MD and ED appear to represent the first examples of
small-molecule allosteric regulators of PDZ–peptide interactions. Leu291 is one of the residues exhibiting stronger
chemical-shift perturbations following covalent attachment of MD than during non-covalent interaction. Leu291 is
the ‘L’ residue in the GLGI motif, the common PDZ-domain loop that forms critical hydrogen bonds with the peptide main-chain carboxylate. It is also the subject of strong chemical-shift perturbation at MD concentrations that
are associated with covalent modification (Figure 5D, red box), and is thus a perfect candidate to mediate conformational cross-talk between the dual ligands. G290 , G292 , and I293 from the GLGI motif also showed chemical-shift
perturbations in both states (Figure 5D, black ovals). Our crystal structure does not show gross displacement of the
carboxylate-binding loop, but we have captured a ternary complex that includes the peptide ligand. As a result, mass
action may have obscured an alternative conformation of the loop. Taken together, our data support the hypothesis
that MD reduces the free energy of an unbound conformation of the loop, rendering the process of peptide binding
less favorable thermodynamically.
Intriguingly, MD appears to act not as a reversible allosteric inhibitor, but rather as a covalent allosteric inhibitor.
There is a small but growing literature on the development of covalent allosteric enzyme inhibitors. For example,
covalent modification on allosteric residue Cys121 can inactivate protein tyrosine phosphatase 1B [48]. Non-catalytic
residues Cys296 and Cys310 of AKT were targeted by effective inhibitors that stabilize the inactive conformation of the
kinase [49]. Covalent modification of the cysteine residue in oncogenic mutant K-RasG12C was found to favor GDP
over GTP binding in the active site and to specifically prevent binding to the downstream effector protein Raf [50].
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Moreover, chemical approaches have been taken to explore the vulnerability of accessible cysteines in cancer therapy
[51].
From the perspective of inhibitor development, lessons can be drawn from the kinase inhibitors: covalent allosteric
inhibitors have shown increased selectivity and potency [49]. Despite the potential concerns of covalent interactions,
there are also advantages: a preference for shallow binding pockets; increased biochemical efficacy; longer duration
and lower effective dose due to a negligible off-rate; and increased specificity by avoiding off-target interactions with
related peptide-binding sites [52,53].
In any case, by acting allosterically, MD appears to exploit a conformational flexibility that is a common feature of
this class of protein–protein interaction modules. Previous studies have shown that PDZ domains can be allosterically
structured by their neighbors. For example, the PDZ2 domain of X11/MINT exhibits WT binding specificity only
when covalently attached to the PDZ1 domain and to the C-terminal tail of the protein [54]. Similarly, in PSD95
PDZ3, an α-helix appended to the C-terminus does not directly contact the peptide but increases the affinity of
peptide binding 21-fold [55]. Spectroscopic studies have identified intramolecular couplings that can provide the
basis of such effects [55,56]. Similarly, statistical interactions based on sequence comparisons of 274 eukaryotic PDZ
domains suggest a free-energy propagation pathway connecting the peptide-binding cleft to the α1 helix and the
other side of the PDZ domain through its core [57]. A similar effect might explain the recent observation that tyrosine
phosphorylation on the back side of the PDZ2 and PDZ3 domains of PSD-95 decreases their peptide-binding affinity
[58]. The prospect of allosteric inhibition expands the potential target surfaces on such protein–protein interaction
domains. In circumventing the relatively flat primary interaction site, this strategy may thus offer new approaches to
address a historically elusive class of targets.
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